M&A market performance suffered in Q3 2023
Deal activity was impacted by several factors including higher inflation and rising interest rates.
Sectors
University of Queensland to begin trial of molecular clamp vaccine
Argenica announces first subject dosing in third cohort of ARG-007 trial
New Zealand MEDSAFE grants approval for Invex’s IIH therapy trial
University of Manchester opens precision medicine trial for rare cancers
Blockchain in clinical trial supply chains: more hype than heft?
Sites on wheels: bringing the clinical trial to the patient’s doorstep
Can AI remedy the growing pains of digital biomarker development?
